What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

OBJECTIVE: To assess clinical outcomes of intolerant, relapsed or refractory patients who could not be treated with new tyrosine kinase inhibitors or experimental therapies. METHODS: A retrospective cohort of 90 chronic myeloid leukemia patients in all phases of the disease treated with imatinib mes...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosi, Guilherme Rasia, Fogliatto, Laura Maria, Costa, Tito Emilio Vanelli, Grokoski, Kamila Castro, Pereira, Mariana Pinto, Bugs, Nathan, Kalil, Marco, Fraga, Christina, Daudt, Liane Esteves, Silla, Lucia Mariano da Rocha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732531/
https://www.ncbi.nlm.nih.gov/pubmed/31085148
http://dx.doi.org/10.1016/j.htct.2018.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732531/
https://www.ncbi.nlm.nih.gov/pubmed/31085148
http://dx.doi.org/10.1016/j.htct.2018.11.005

Ejemplares similares